240
Participants
Start Date
January 17, 2023
Primary Completion Date
November 30, 2027
Study Completion Date
December 31, 2027
SKB264
be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;
Pembrolizumab
be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;
Icon Cancer Centre Wesley, Auchenflower
Westchester Medical Center, Hawthorne
Anne Arundel Medical Center (AAMC), Annapolis
Oncology & Hematology Associates of Southwest Virginia, Inc. Roanoke, VA, Roanoke
Norton Cancer Institute, Louisville
Community Clinical Research Center, Anderson
Texas Oncology, P.A. Austin, TX, Austin
UT Health East Texas - Hope Cancer Center Tyler, Tyler
Texas Oncology, P.A. Amarillo, TX, Amarillo
Flinders Medical Centre, Bedford Park
Wollongong Hospital, Kogarah
Algemeen Ziekenhuis Klina, Brasschaat
Grand Hôpital de Charleroi - Site Notre-Dame, Charleroi
Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert
Centre Hospitalier de l'Université de Montréal (CHUM), Montreal
Sun Yat-Sen University Cancer Center, Guangzhou
Affiliated Cancer Hospital of Guangxi Medical University, Nanning
Hubei Cancer Hospital, Wuhan
Hunan Cancer Hospital, Changsha
Jilin Cancer Hospital, Changchun
The Second Hospital of Dalian, Dalian
Weifang People's Hospital, Weifang
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing
Peking University First Hospital, Beijing
The First Affiliated Hospital of Jilin University, Changchun
Hunan Cancer Hospital, Changsha
Chongqing Cancer Hospital, Chongqing
Sun Yat-sen Memorial Hospital, Guangzhou
Sun Yat-Sen University Cancer Center, Guangzhou
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
Zhejiang Provincial People's Hospital, Hangzhou
Qilu Hosptial of Qlilu University, Jinan
Shandong Cancer Hospital, Jinan
Nanjing Drum Tower Hospital, Nanjing
Fudan University Shanghai Cancer Center, Shanghai
Obstetrics and Gynecology Hospital Affiliated to Fudan University, Shanghai
Liaoning Cancer Hospital & Institute, Shenyang
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan
Zhongnan Hospital of Wuhan University, Wuhan
Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou Universit, Zhengzhou
Henan Cancer Hospital, Zhengzhou
The first Affiliated Hospital of Zhengzhou University, Zhengzhou
Szpitale Pomorskie Sp. z o.o., Gdynia
Biokinetica S.A., Przychodnia Jozefow, Warsaw
BC Cancer - Kelowna, Kelowna
Pratia MCM Krakow, Krakow
Lead Sponsor
Myriad Genetics, Inc.
INDUSTRY
Discovery Life Sciences, LLC
UNKNOWN
Ventana Medical Systems, Inc
UNKNOWN
Frontage Laboratories, Inc.
UNKNOWN
Clario
UNKNOWN
Klus Pharma Inc.
INDUSTRY